Blog
About

54
views
0
recommends
+1 Recommend
0 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: not found

      Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer.

      The New England journal of medicine

      Topoisomerase I Inhibitors, Survival Analysis, Single-Blind Method, metabolism, antagonists & inhibitors, Receptor, Epidermal Growth Factor, Neoplasm Metastasis, Middle Aged, Male, Humans, Female, chemically induced, Exanthema, Disease Progression, pathology, mortality, drug therapy, Colorectal Neoplasms, analogs & derivatives, adverse effects, administration & dosage, Camptothecin, therapeutic use, Antineoplastic Combined Chemotherapy Protocols, Antineoplastic Agents, Antibodies, Monoclonal, Humanized, Antibodies, Monoclonal, Aged, 80 and over, Aged, Adult, secondary, Adenocarcinoma

      Read this article at

      ScienceOpenPublisherPubMed
      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          The epidermal growth factor receptor (EGFR), which participates in signaling pathways that are deregulated in cancer cells, commonly appears on colorectal-cancer cells. Cetuximab is a monoclonal antibody that specifically blocks the EGFR. We compared the efficacy of cetuximab in combination with irinotecan with that of cetuximab alone in metastatic colorectal cancer that was refractory to treatment with irinotecan. We randomly assigned 329 patients whose disease had progressed during or within three months after treatment with an irinotecan-based regimen to receive either cetuximab and irinotecan (at the same dose and schedule as in a prestudy regimen [218 patients]) or cetuximab monotherapy (111 patients). In cases of disease progression, the addition of irinotecan to cetuximab monotherapy was permitted. The patients were evaluated radiologically for tumor response and were also evaluated for the time to tumor progression, survival, and side effects of treatment. The rate of response in the combination-therapy group was significantly higher than that in the monotherapy group (22.9 percent [95 percent confidence interval, 17.5 to 29.1 percent] vs. 10.8 percent [95 percent confidence interval, 5.7 to 18.1 percent], P=0.007). The median time to progression was significantly greater in the combination-therapy group (4.1 vs. 1.5 months, P<0.001 by the log-rank test). The median survival time was 8.6 months in the combination-therapy group and 6.9 months in the monotherapy group (P=0.48). Toxic effects were more frequent in the combination-therapy group, but their severity and incidence were similar to those that would be expected with irinotecan alone. Cetuximab has clinically significant activity when given alone or in combination with irinotecan in patients with irinotecan-refractory colorectal cancer. Copyright 2004 Massachusetts Medical Society

          Related collections

          Author and article information

          Journal
          10.1056/NEJMoa033025
          15269313

          Comments

          Comment on this article